• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Omidria (phenylephrine and ketorolac injection)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Omidria (phenylephrine and ketorolac injection)

  • Profile

Profile

Contact Information

Contact: Omeros
Website: http://www.omidria.com/

Currently Enrolling Trials

    Show More

    General Information

    Omidria (phenylephrine and ketorolac injection) is a combination of an anti-inflammatory agent and a mydriatic agent (causes pupil dilation, called mydriasis).

    Omidria is specifically indicated for use during cataract surgery or intraocular lens replacement for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

    Mechanism of Action

    Omidria contains the active ingredients phenylephrine and ketorolac. Phenylephrine is an a1-adrenergic receptor agonist and, in the eye, acts as a mydriatic agent by contracting the radial muscle of the iris. Ketorolac is a nonsteroidal anti-inflammatory that inhibits both cyclooxygenase enzymes (COX-1 and COX-2), resulting in a decrease in tissue concentrations of prostaglandins to reduce pain due to surgical trauma. Ketorolac, by inhibiting prostaglandin synthesis secondary to ocular surgical insult or direct mechanical stimulation of the iris, also prevents surgically induced miosis.

    Side Effects

    Adverse effects associated with the use of Omidria may include, but are not limited to, the following:

    • Eye irritation
    • Posterior capsule opacification
    • Increased intraocular pressure
    • Anterior chamber inflammation

    Dosing/Administration

    Omidria is supplied as a solution for intraocular administration. For administration, 4 mL of Omidria is diluted in 500 mL of ophthalmic irrigation solution. Irrigation solution is to be used as needed for the surgical procedure.

    Clinical Trial Results

    FDA Approval

    The FDA approval of Omidria was based on three phase 3 randomized, multicenter, double-masked, placebo-controlled clinical trials in 808 adult subjects undergoing cataract surgery or intraocular lens replacement. Subjects were randomized to either Omidria or placebo. Subjects were treated with preoperative topical mydriatic and anesthetic agents. Pupil diameter was measured throughout the surgical procedure. Postoperative pain was evaluated by self-administered 0-100 mm visual analog scales (VAS). Mydriasis was maintained in the Omidria-treated groups while the placebo-treated groups experienced progressive constriction. At the end of cortical clean-up, 23 percent of placebo-treated subjects and 4 percent of Omidria-treated subjects had a pupil diameter less than 6 mm (p < 0.01). Pain during the initial 10 to 12 hours postoperatively was statistically significantly less in the Omidria-treated groups than in the placebo-treated groups. During the 10 to 12 hours postoperatively, 26 percent of Omidria-treated subjects reported no pain (VAS = 0 at all timepoints) while 17 percent of placebo-treated subjects reported no pain (p < 0.01). 

     

     

    Approval Date: 2014-06-01
    Company Name: Omeros
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing